Skip to main content

Table 3 Glucose and cardiovascular parameters in patients taking vildagliptin (100 mg daily) or sitagliptin (50 mg daily)

From: Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)

 

vildagliptin

sitagliptin

p-value

HbA1c (%)

7.54 ± 0.93

7.64 ± 0.93

0.211

GA (%)

19.8 ± 3.47

20.1 ± 3.31

0.087

1,5AG (μg/mL)

7.68 ± 5.60

7.49 ± 6.16

0.389

IRI (μU/mL)

7.26 ± 4.44

6.94 ± 4.37

0.735

CPR (ng/mL)

2.14 ± 0.92

1.95 ± 0.78

0.302

U-CPR (μ/day)

97.0 ± 41.6

85.2 ± 39.9

0.008*

BNP (pg/mL)

7.00 ± 9.24

8.03 ± 8.40

0.283

PAI-1 (ng/mL)

36.6 ± 14.9

40.6 ± 23.1

0.231

  1. GA = glycoalbumin; 1,5-AG = 1,5-anhydroglucitol; IRI = immunoreactive insulin; CPR = C-peptide immunoreactivity; BNP = brain natriuretic peptide; PAI-1 = plasminogen activator inhibitor-1.
  2. Data are mean ± standard deviation. Paired-sample t-test. * p < 0.05.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840